Page last updated: 2024-11-13

substance p, phe(5)-trp(7,9)-leu(11)-

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

substance P, Phe(5)-Trp(7,9)-Leu(11)-: substance P antagonist; bombesin antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID25077998
CHEMBL ID3586019
MeSH IDM0133006

Synonyms (18)

Synonym
antd
1-d-arginine-5-d-phenylalanine-7-d-tryptophan-9-d-tryptophan-11-l-leucinamide- substance p
apttl-sp
d-arg(10)-d-phe(5)-d-trp(7,9)-leu(11)-sp
substance p-pttl
substance p, 1-d-arginine-5-d-phenylalanine-7-d-tryptophan-9-d-tryptophan-11-l-leucinamide-
1-arg-5-phe-7,9-trp-11-leu-substance p
substance p, phe(5)-trp(7,9)-leu(11)-
substance p, d-arg(10)-d-phe(5)-d-trp(7,9)-leu(11)-
(arg(1),phe(5),trp(7,9),leu(11))-substance p
substance p, arg(1)-phe(5)-trp(7,9)-leu(11)-
substance p, phenylalanyl(5)-tryptophyl(7,9)-leucine(11)-
5-phenylalanyl-7,9-tryptophyl-11-leucine-substance p
l-756,867
5-phe-7,9-trp-11-leu-substance p
substance p, arginyl(1)-phenylalanyl(5)-tryptophyl(7,9)-leucyl(11)-
CHEMBL3586019 ,
bdbm50097492

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves of neuropeptide-induced inositol phosphate generation were dramatically displaced to the right by either 10 microM AntD or 20 microM AntG."( Substance P-related antagonists inhibit vasopressin and bombesin but not 5'-3-O-(thio)triphosphate-stimulated inositol phosphate production in Swiss 3T3 cells.
Freemont, PS; Newman, RH; Rozengurt, E; Seckl, MJ, 1995
)
0.29
" At a concentration of 50 nM, L-756,867 shifted the dose-response curve of L-692,429-induced GH release to the right by about tenfold."( Inhibition of L-692,429-stimulated rat growth hormone release by a weak substance P antagonist: L-756,867.
Butler, B; Chan, WW; Chaung, LY; Cheng, K; Smith, RG; Wei, L, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Growth hormone secretagogue receptor type 1Rattus norvegicus (Norway rat)IC50 (µMol)0.13370.00520.11530.2500AID1231852; AID1231853; AID1231854
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGrowth hormone secretagogue receptor type 1Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1231854Inverse agonist activity at rat ghrelin receptor by inositol phosphate turnover assay2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
2-Aminoalkyl nicotinamide derivatives as pure inverse agonists of the ghrelin receptor.
AID1231853Inverse agonist activity at rat ghrelin receptor expressed in HEK293 cells by inositol phosphate turnover assay2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
2-Aminoalkyl nicotinamide derivatives as pure inverse agonists of the ghrelin receptor.
AID1231852Inverse agonist activity at rat ghrelin receptor expressed in HEK293 cells by NFAT-RE-luciferase reporter gene assay2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
2-Aminoalkyl nicotinamide derivatives as pure inverse agonists of the ghrelin receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (6.06)18.7374
1990's15 (45.45)18.2507
2000's7 (21.21)29.6817
2010's9 (27.27)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.66 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other32 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]